Synopsis Acute myeloid leukemia (AML) in elderly patients has a poor prognosis. In an attempt to improve outcome for these patients, this trial was conducted by randomly assigning patients to a standard induction regimen with lomustine. The present study aims to assess the impact of lomustine when added to idarubicin and cytarabine during induction and post-remission therapy in elderly patients with non-adverse cytogenetics. This week’s “ MED FACT ” discusses a randomized control trial from Journal of Clinical Oncology, “ Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial ”. Authors: A.
Pigneux, et. al. Key Takeaways Adding lomustine to standard chemotherapy significantly improved the overall survival of elderly patients with AML. Objective: The present study aims to…
